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A bs tr ac t
Background
The use of high-flow nasal cannulae is an increasingly popular alternative to nasal 
continuous positive airway pressure (CPAP) for noninvasive respiratory support of 
very preterm infants (gestational age, <32 weeks) after extubation. However, data 
on the efficacy or safety of such cannulae in this population are lacking.
Methods
In this multicenter, randomized, noninferiority trial, we assigned 303 very preterm 
infants to receive treatment with either high-flow nasal cannulae (5 to 6 liters per 
minute) or nasal CPAP (7 cm of water) after extubation. The primary outcome was 
treatment failure within 7 days. Noninferiority was determined by calculating the 
absolute difference in the risk of the primary outcome; the margin of noninferiority 
was 20 percentage points. Infants in whom treatment with high-flow nasal can-
nulae failed could be treated with nasal CPAP; infants in whom nasal CPAP failed 
were reintubated.
Results
The use of high-flow nasal cannulae was noninferior to the use of nasal CPAP, with 
treatment failure occurring in 52 of 152 infants (34.2%) in the nasal-cannulae 
group and in 39 of 151 infants (25.8%) in the CPAP group (risk difference, 8.4 per-
centage points; 95% confidence interval, −1.9 to 18.7). Almost half the infants in 
whom treatment with high-flow nasal cannulae failed were successfully treated 
with CPAP without reintubation. The incidence of nasal trauma was significantly 
lower in the nasal-cannulae group than in the CPAP group (P = 0.01), but there were 
no significant differences in rates of serious adverse events or other complications.
Conclusions
Although the result for the primary outcome was close to the margin of noninferi-
ority, the efficacy of high-flow nasal cannulae was similar to that of CPAP as respi-
ratory support for very preterm infants after extubation. (Funded by the National 
Health and Medical Research Council; Australian New Zealand Clinical Trials Net-
work number, ACTRN12610000166077.)
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In the United States, approximately 75,000 infants were classified as very preterm (gestational age, <32 weeks) in 2011.1 Very 
preterm infants have substantially higher mor-
tality and morbidity than term infants, partly be-
cause they are more prone to respiratory failure 
and often require mechanical ventilation through 
an endotracheal tube after birth. Once they re-
cover from their acute breathing problems, the 
best way to achieve successful extubation from 
mechanical ventilation is controversial. Nasal con-
tinuous positive airway pressure (CPAP) is known 
to be superior to no positive-pressure support2 
and is the current standard of care for noninvasive 
respiratory support of very preterm infants.
The use of high-flow nasal cannulae is an 
alternative means of providing noninvasive re-
spiratory support to very preterm infants. Such 
cannulae deliver heated and humidified gas at 
flow rates of more than 1 liter per minute 
through small binasal prongs. Because high-flow 
nasal cannulae have a simpler interface with the 
infant and smaller prongs than nasal CPAP, the 
cannulae are perceived as easier to use, more 
comfortable for the infant, and advantageous for 
mother–infant bonding.3,4 The use of high-flow 
nasal cannulae is increasingly popular for non-
invasive respiratory support in neonatal intensive 
care units around the world.3,5 In 2008, the de-
vices were being used in up to two thirds of 
academic neonatal units in the United States.6 
High-flow nasal cannulae are used to prevent 
extubation failure in preterm infants, with pre-
scribed flow rates typically ranging from 2 to 
8 liters per minute.3,7,8 However, there is little 
evidence regarding the risks and benefits of this 
new technique.9,10 Several mechanisms of action 
of high-flow nasal cannulae in preterm infants 
have been described,11 but the contribution of 
each is undefined. Furthermore, concern has 
been raised that the generation of unregulated 
distending pressure from high-flow nasal can-
nulae might injure the lungs.12,13
We hypothesized that high-flow nasal cannu-
lae are an appropriate alternative to nasal CPAP, 
even if the devices do not provide superior respi-
ratory support. We performed a multicenter, 
randomized, noninferiority trial of high-flow 
nasal cannulae, as compared with nasal CPAP, 
as respiratory support after extubation in pre-
term infants born at a gestational age of less 
than 32 weeks.
Me thods
Study Design and Oversight
From May 31, 2010, to July 3, 2012, we recruited 
infants in three Australian neonatal intensive care 
units at the Royal Women’s Hospital, Melbourne; 
Women’s and Children’s Hospital, Adelaide; and 
the Royal Brisbane and Women’s Hospital, Bris-
bane. The trial was designed and conducted by 
the authors. The human research ethics commit-
tee at each center approved the trial. The study 
was funded by the participating neonatal units 
and by the National Health and Medical Research 
Council. All authors vouch for the accuracy and 
completeness of the data and the fidelity of the 
study to the protocol, which is available with the 
full text of this article at NEJM.org. There was no 
commercial support for this study.
Patients
Infants were eligible if they were born at a gesta-
tional age of less than 32 weeks, were receiving 
mechanical ventilation through an endotracheal 
tube, and were scheduled to undergo extubation 
for the first time to noninvasive respiratory sup-
port. Infants were ineligible if their gestational 
age was more than 36 weeks at the time of extu-
bation, if they were participating in a concurrent 
study that prohibited inclusion, if they had a 
known major congenital anomaly that might af-
fect breathing, or if maximal intensive care was 
not being provided. All parents or guardians pro-
vided written informed consent.
Randomization
A computer-generated block-randomization se-
quence with random block sizes was used. All 
infants were stratified according to gestational 
age (<26 weeks vs. ≥26 weeks) and study center. 
Infants who were part of multiple births under-
went individual randomization. Clinicians opened 
consecutively numbered, sealed, opaque enve-
lopes immediately before extubation to deter-
mine the study-group assignment. In the case of 
an unplanned extubation in an infant for whom 
consent had already been obtained, randomiza-
tion occurred if the treating physician decided to 
provide noninvasive respiratory support. If the 
infant required resuscitation and immediate re-
intubation, randomization did not occur, and the 
infant remained eligible for inclusion with the 
next planned extubation.
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Study Intervention
Infants received oral or intravenous caffeine (ei-
ther a loading dose of 20 mg per kilogram of 
body weight or a maintenance dose of 5 to 10 mg 
per kilogram) in the 24 hours before extubation. 
The treating physician made the decision to extu-
bate an infant before randomization. Infants re-
ceived their assigned treatment immediately af-
ter extubation. Treatment was considered to have 
failed if an infant who was receiving maximal 
respiratory support with the assigned treatment 
met one or more of the following four criteria for 
failure within 7 days after extubation: a fraction 
of inspired oxygen of 0.2 or more above the base-
line value before extubation that was required to 
maintain a peripheral oxygen saturation of 88 to 
92%; a pH of less than 7.2 and a partial pressure 
of carbon dioxide of more than 60 mm Hg on an 
arterial or free-flowing capillary blood gas sam-
ple; more than one apneic episode requiring in-
termittent positive-pressure ventilation within a 
24-hour period or six or more apneic episodes 
requiring stimulation within 6 consecutive hours; 
or an urgent need for reintubation and mechan-
ical ventilation, as determined by the treating 
physician.
Infants in the nasal-cannulae group were 
treated with the Optiflow device, which included 
the MR850 humidifier and binasal infant can-
nulae (Fisher & Paykel Healthcare). Infants were 
fitted with prongs that maintained a leak at the 
nose, with the aim of occluding approximately 
half the nares. The device includes a pressure-
relief valve that limits circuit pressure to 45 cm 
of water. The starting flow rate was based on the 
size of the prongs used, with 5 liters per minute 
for “premature” or “neonatal” prongs or 6 liters 
per minute for “infant,” “intermediate infant,” 
or “pediatric” prongs. Flow rates were altered at 
the physician’s discretion in a stepwise fashion, 
with mandated limits between 2 liters per min-
ute and the maximum recommended for the 
prong size: 6 liters per minute for “premature” 
and “neonatal” prongs, 7 liters per minute for 
“infant” or “intermediate infant” prongs, and 
8 liters per minute for “pediatric” prongs. For 
infants who were weaned to 2 liters per minute 
and who had a fraction of inspired oxygen of 
less than 0.3 for more than 24 hours, treatment 
with the high-flow nasal cannulae could be 
stopped, although such cessation of therapy was 
not mandatory, and earlier cessation was or-
dered at the discretion of the treating team if the 
fraction of inspired oxygen was less than 0.3.
Infants in whom treatment with high-flow 
nasal cannulae failed were treated with nasal 
CPAP (7 cm of water), with the same pressure 
limits as those used in the CPAP group. If the 
CPAP treatment failed under the maximal pres-
sure during the first 7 days after extubation, 
infants were reintubated.
Infants in the CPAP group were started on a 
pressure of 7 cm of water with either binasal 
midline prongs (Fisher & Paykel Healthcare) or 
subnasal prongs (Hudson RCI), depending on 
the practice in the individual unit. Nasal CPAP 
was generated with the use of a mechanical ven-
tilator or an underwater “bubble” system. Pres-
sures were altered at the physician’s discretion, 
within limits of 5 to 8 cm of water during the 
first 7 days after extubation. Nonsynchronized 
nasal intermittent positive-pressure ventilation 
could be used at the time of extubation or at any 
later time during the admission, with a maxi-
mum inflating pressure of 25 cm of water and a 
maximum rate of 40 inflations per minute. Once 
infants were weaned to a nasal CPAP of 5 cm of 
water with a fraction of inspired oxygen of less 
than 0.3 for more than 24 hours, nasal CPAP could 
be discontinued. Infants in whom CPAP treatment 
failed at a maximal pressure of 8 cm of water 
(with or without nonsynchronized nasal intermit-
tent positive-pressure ventilation) were reintubated. 
Infants in the CPAP group were not permitted to 
receive treatment with high-flow nasal cannulae at 
any time during their admission.
Study Outcomes
The primary outcome was treatment failure 
within 7 days (168 hours) after extubation. Pre-
specified secondary outcomes included reintuba-
tion during the primary-outcome period, death 
before hospital discharge, a requirement for sup-
plemental oxygen at a gestational age of 36 weeks, 
pneumothorax after trial entry, total days of any 
respiratory support after trial entry, duration of 
oxygen supplementation after trial entry, and 
length of hospital admission. Nursing and medi-
cal staff members, who were aware of study-
group assignments, regularly assessed the nasal 
skin and septum for trauma caused by pressure 
from the binasal prongs. Data included the inci-
dence of any nasal trauma, its cause, and the need 
for change of treatment because of nasal trauma.
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Serious adverse events were predefined as 
pneumothorax occurring while the infants re-
ceived the assigned treatment and death. These 
events were reported to the principal investiga-
tor and the relevant ethics committee as they 
occurred. Data were collected until death or the 
first discharge home from the hospital.
Statistical Analysis
We estimated that extubation would have a fail-
ure rate of 25% for very preterm infants on the 
basis of a review of 2 years of data from the lead 
center (the Royal Women’s Hospital, Melbourne), 
where high-flow nasal cannulae had not been 
used previously. We prespecified the margin of 
noninferiority for high-flow nasal cannulae as 
20 percentage points above the failure rate for 
nasal CPAP. Since little guidance was available 
for such a comparison, the choice of margin was 
somewhat arbitrary. Our rationale was that many 
clinicians already strongly prefer the use of high-
flow nasal cannulae, and the devices are in wide-
spread use because of their perceived benefits over 
nasal CPAP. We allowed the use of “rescue” nasal 
CPAP for infants in whom treatment with high-
flow nasal cannulae failed. This procedure reflected 
303 Underwent randomization
1099 Infants born at <32 wk of gestational age
were screened for eligibility
622 Were ineligible
530 Did not undergo ventilation
30 Died before extubation
25 Were excluded
15 Had major congenital anomaly
8 Were included in another extubation
study
2 Had gestational age ≥36 wk
14 Were extubated to no support
13 Received palliative care
10 Were extubated at another hospital
 
477 Were eligible
174 Did not undergo randomization
    77 Were not approached
    34 Had consent declined 
    28 Had medical reasons
    19 Were unable to have consent provided
         for social reasons
    10 Had unplanned extubation
6 Had consent provided but did not undergo 
 randomization
3 Died before randomization
2 Had consent withdrawn
1 Missed randomization
152 Were assigned to high-flow nasal
cannulae
151 Were assigned to nasal CPAP
152 Were included in primary analysis 151 Were included in primary analysis
Figure 1. Enrollment and Outcomes.
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clinical practice around the world at centers where 
both treatments are commonly available.
The primary outcome was short-term treat-
ment efficacy, rather than death or disability, for 
which a lower noninferiority margin might be 
recommended.14 Noninferiority was determined 
by calculating the absolute risk difference and 
95% confidence interval for the primary out-
come. For treatment with high-flow nasal can-
nulae to be noninferior, the upper limit of the 
95% confidence interval had to be below 20 per-
centage points, and the lower limit of the 95% 
confidence interval had to be below zero.14 We 
determined that a sample of 300 infants was 
required to show noninferiority for high-flow 
nasal cannulae with a power of 87%.
All analyses were performed on an intention-
to-treat basis, and infants remained in their as-
signed group for all outcomes. For the primary 
outcome and dichotomous secondary outcomes, 
we calculated the difference between the groups 
using risk differences and 95% confidence inter-
vals. We used chi-square tests to compare second-
ary dichotomous outcomes and the appropriate 
parametric test (Student’s t-test) or nonparamet-
ric test (Wilcoxon rank-sum test) to compare 
continuous outcomes. An independent data and 
safety monitoring committee performed two 
interim analyses, when the primary outcome 
was known for 100 infants and for 200 infants, 
and on the basis of each analysis recommended 
that the study continue unaltered. All analyses 
were performed with the use of Stata/IC soft-
ware, version 12.0 (StataCorp).
Table 1. Characteristics of the Infants and Their Mothers.*
Characteristic
Nasal-Cannulae Group
(N = 152)
CPAP Group
(N = 151)
Mothers
White race — no. (%)† 127 (83.6) 120 (79.5)
Primigravida — no. (%) 61 (40.1) 59 (39.1)
Exposure to antenatal glucocorticoids — no. (%) 142 (93.4) 143 (94.7)
Cesarean section — no. (%) 101 (66.4) 101 (66.9)
Infants
Gestational age
No. of wk 27.7±2.1 27.5±1.9
<26 wk — no. (%) 32 (21.1) 31 (20.5)
Birth weight — g 1041±338 1044±327
Male sex — no. (%) 89 (58.6) 72 (47.7)
Multiple birth — no. (%) 49 (32.2) 52 (34.4)
Intubated in the delivery room — no. (%) 102 (67.1) 91 (60.3)
Median Apgar score at 5 min (IQR) 7 (6–8)‡ 8 (6–8)
Surfactant treatment — no. (%) 141 (92.8) 144 (95.4)
Caffeine treatment before extubation — no. (%) 151 (99.3) 148 (98.0)
Median postnatal age at extubation (IQR) — hr 43.2 (20.8–115.7) 38.5 (22.8–101.7)
Median duration of mechanical ventilation before  
extubation (IQR) — hr
 36 (19.5–101.5) 36 (20–93)
pH before extubation§ 7.33±0.06  7.32±0.06
Partial pressure of carbon dioxide before extubation — 
mm Hg§
44.2±9.2 43.6±9.0
Fraction of inspired oxygen before extubation 0.23±0.04  0.23±0.04
* Plus–minus values are means ±SD. There were no significant differences between the two groups. CPAP denotes con-
tinuous positive airway pressure, and IQR interquartile range.
† Race was reported by the investigators.
‡ The Apgar score was not known for three infants.
§ Blood gas results were from capillary (heel-prick) or arterial blood samples.
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R esult s
Study Patients
A total of 303 infants underwent randomization 
(152 to the nasal-cannulae group and 151 to the 
CPAP group) during the study period (Fig. 1). The 
demographic and clinical characteristics of the 
mothers and infants in the two groups were sim-
ilar (Table 1).
Primary Outcome
The use of high-flow nasal cannulae was found 
to be noninferior to the use of nasal CPAP by our 
definition, with treatment failure occurring in 
52 of 152 infants (34.2%) in the nasal-cannulae 
group and 39 of 151 infants (25.8%) in the CPAP 
group (risk difference, 8.4 percentage points; 
95% confidence interval, −1.9 to 18.7). Treatment 
failure stratified according to gestational-age 
subgroup is provided in Table S1 in the Supple-
mentary Appendix, available at NEJM.org.
The most common reason for treatment fail-
ure in the two study groups was apnea (Table 2), 
with no significant between-group difference in 
the reason for failure. Failure was most likely to 
occur during the first day after extubation in the 
two groups (Fig. 2).
Reintubation during the First 7 Days  
after Extubation
Of the 52 infants in whom treatment with high-
flow nasal cannulae failed during the first 7 days 
after extubation, 25 (48%) were successfully treat-
ed with nasal CPAP or nonsynchronized nasal 
intermittent positive-pressure ventilation without 
reintubation. Thus, only 17.8% of infants in the 
nasal-cannulae group were reintubated, as com-
pared with 25.2% of those in the CPAP group 
(P = 0.12) (Table 2). In the latter group, 3 infants 
received nonsynchronized nasal intermittent 
positive-pressure ventilation immediately after 
extubation, and 36 infants (23.8%) received non-
Table 2. Reasons for Treatment Failure, Reintubation, and Other Secondary Outcomes.
Outcome
Nasal-Cannulae Group 
(N = 152)
CPAP Group
(N = 151)
Risk Difference 
(95% CI)* P Value
percentage points
Reason for treatment failure — no./ 
total no. (%)†
Apnea 32/52 (61.5) 25/39 (64.1) −2.6 (−22.6 to 17.5) 0.80
Increase in fraction of inspired  
oxygen
21/52 (40.4) 20/39 (51.3) −10.9 (−31.5 to 9.7) 0.30
Respiratory acidosis 6/52 (11.5)‡ 2/39 (5.1) 6.4 (−4.7 to 17.5) 0.29
Urgent need for intubation 2/52 (3.8) 4/39 (10.3) −6.4 (−17.3 to 4.5) 0.22
Reintubation within 7 days after  
extubation — no. (%)
27 (17.8) 38 (25.2) −7.4 (−16.6 to 1.8) 0.12
Median no. of days of respiratory sup-
port after trial entry (IQR)§¶
34 (7 to 55) 38 (11 to 57) NA 0.44
Median no. of days of oxygen therapy 
after trial entry (IQR)¶‖
38 (0 to 78) 49 (8 to 83) NA 0.15
Median weight gain during first 7 days 
after extubation (IQR) — g
    20 (−42 to 79.5) 10 (−54 to 75) NA 0.39
Median discharge weight (IQR) — g¶    2886 (2515 to 3290)      2950 (2500 to 3524) NA 0.53
Median no. of days in a tertiary care 
center (IQR)¶
 65 (43 to 91) 64 (45 to 104) NA 0.56
Median no. of days in any hospital (IQR)¶   79 (63 to 105) 84 (65 to 106) NA 0.38
* Positive values favor the CPAP group, and negative values favor the nasal-cannulae group.
† Treatment may have failed for more than one reason. In one infant in the CPAP group, treatment failed because a set 
pressure of more than 8 cm of water was prescribed during the primary-outcome period.
‡ One infant had a measured pH of exactly 7.20, and one infant had a measured pH of 7.21.
§ Respiratory support included the use of high-flow nasal cannulae, nasal CPAP, nonsynchronized nasal intermittent  
positive-pressure ventilation, and mechanical ventilation through an endotracheal tube.
¶ Infants who died before discharge were excluded.
‖ This category includes only hospital days, even though some infants received oxygen therapy after being discharged.
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synchronized nasal intermittent positive-pressure 
ventilation during the first 7 days after extuba-
tion; of these infants, 22 were reintubated after 
treatment failure.
Other Secondary Outcomes and Adverse Events
There were no significant between-group differ-
ences in rates of other secondary outcomes (Ta-
ble 2) or in rates of death or other serious adverse 
events (Table 3). The pneumothorax rate after 
trial entry was low in the two study groups. In 
the nasal-cannulae group, infants had a signifi-
cantly lower incidence of nasal trauma than those 
in the CPAP group (39.5% vs. 54.3%, P = 0.01), and 
fewer infants required a change in therapy be-
cause of nasal trauma (P = 0.001). No infant in 
either group required surgical correction for na-
sal trauma. Almost half the cases of nasal trau-
ma in the nasal-cannulae group were diagnosed 
while the infants were receiving other types of 
noninvasive respiratory support. If the diagnosis 
of nasal trauma was limited to cases that were 
diagnosed during the assigned treatment, the 
between-group difference was greater, with a 
rate of 19.1% in the nasal-cannulae group versus 
53.0% in the CPAP group (P<0.001).
Discussion
On the basis of our prespecified definition of 
noninferiority, the use of high-flow nasal can-
nulae was noninferior to the use of nasal CPAP as 
respiratory support for very preterm infants after 
extubation, with a between-group difference of 
8.4 percentage points that favored CPAP. When 
treatment with high-flow nasal cannulae failed, 
about half the infants were successfully treated 
with CPAP without reintubation, resulting in a 
nonsignificant between-group difference in the 
rate of reintubation within 7 days after extuba-
tion. Among infants in the nasal-cannulae group, 
there was no increase in rates of death or compli-
cations and there was a decrease in the rate of 
nasal trauma, as compared with the CPAP group.
The use of high-flow nasal cannulae has been 
widely adopted without evidence of safety and ef-
ficacy. The results of two small, randomized trials 
of these devices, as compared with nasal CPAP, 
after extubation have been reported previously. 
Both these trials were conducted in a single center 
and had a superiority design. In the study by 
Campbell et al.,15 40 infants with a birth weight 
of less than 1250 g were randomly assigned to 
one of the two treatments after extubation. Sig-
nificantly more infants in the nasal-cannulae 
group required reintubation within 7 days, prob-
ably because of the reduced flow rates (<2 liters 
per minute) that were used. In the study by Col-
lins et al.,16 which involved 132 very preterm in-
fants, the investigators used a different high-flow 
nasal-cannulae device (Vapotherm) and an in-
creased flow rate (8 liters per minute) after extu-
bation. They found no significant between-group 
difference in the primary outcome of treatment 
failure within 7 days and no significant difference 
in reintubation rates, although the authors ac-
knowledged that the study was underpowered for 
these outcomes. Nasal-trauma scores were lower 
in the nasal-cannulae group than in the CPAP 
group, which is consistent with our findings.
In our multicenter trial, 63 of the infants had 
a gestational age of less than 26 weeks, but the 
study was not powered to evaluate the efficacy 
or safety of high-flow nasal cannulae in this ex-
tremely preterm subgroup. The treatment-failure 
rate was very high among these infants, regard-
less of the assigned treatment, and the risk dif-
ference was 20 percentage points in favor of nasal 
CPAP (see the Supplementary Appendix). Given 
this finding, we think that clinicians should be 
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Figure 2. Very Preterm Infants without Treatment Failure after Extubation.
Shown are the percentages of very preterm infants (gestational age, <32 weeks) 
in whom treatment with either high-flow nasal cannulae or nasal continuous 
positive airway pressure (CPAP) did not fail after extubation during the primary 
outcome period (7 days). Treatment failure occurred in 52 of 152 infants (34.2%) 
in the nasal-cannulae group and 39 of 151 infants (25.8%) in the CPAP group 
(risk difference, 8.4 percentage points).
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cautious before using high-flow nasal cannulae 
as first-line respiratory support in extremely 
preterm infants after extubation. The risk dif-
ference for treatment failure among infants 
with a gestational age of 26 weeks or more was 
5 percentage points.
The results of our trial pertain only to infants 
who have been extubated and should not be ex-
trapolated to the use of high-flow nasal cannulae 
as primary respiratory support after birth. We used 
the Fisher & Paykel high-flow nasal-cannulae sys-
tem in our trial, but there is no evidence that any 
one commercially available system is superior to 
another.17 The flow rates for the nasal cannulae 
that we used have been shown to result in dis-
tending pressures in vivo that are similar to, or 
slightly lower than, commonly set nasal CPAP 
pressures.18-20 Since it was not possible to blind 
the intervention, we used prespecified, objective 
criteria for treatment failure as the primary out-
come to minimize bias.
We allowed the use of rescue nasal CPAP in the 
nasal-cannulae group only after treatment failure. 
We acknowledge that this may have influenced 
some of the secondary outcomes in the nasal-
cannulae group. Because the use of nasal CPAP 
prevented the reintubation of almost half the in-
fants in whom treatment with nasal cannulae had 
failed, it seems reasonable to use high-flow nasal 
cannulae initially after extubation if both therapies 
are available. In our trial, nonsynchronized nasal 
intermittent positive-pressure ventilation could be 
used in infants receiving nasal CPAP. If the use 
of nonsynchronized nasal intermittent positive-
Table 3. Adverse Events.
Event
Nasal-Cannulae 
Group
(N = 152)
CPAP 
Group
(N = 151)
Risk Difference  
(95% CI)* P Value
no. (%) percentage points
Death before discharge† 5 (3.3) 6 (4.0) −0.7 (−4.9 to 3.5) 0.75
Oxygen supplementation at gestational age of  
36 wk
47 (30.9) 52 (34.4) −3.5 (−14.1 to 7.0) 0.51
Glucocorticoid treatment for lung disease after 
 trial entry
27 (17.8) 30 (19.9) −2.1 (−10.9 to 6.7) 0.64
Pneumothorax
Anytime after trial entry 1 (0.7) 4 (2.6) −2.0 (−4.9 to 0.9) 0.17
During assigned treatment† 0 1 (0.7) −0.6 (−1.9 to 0.6) 0.32
Discharged home with oxygen‡ 21 (13.8) 15 (9.9) 3.9 (−3.4 to 11.2) 0.30
Proven sepsis after trial entry 26 (17.1) 30 (19.9) −2.8 (−11.5 to 6.0) 0.54
Patent ductus arteriosus treated with medication 
or surgery
64 (42.1) 64 (42.4) −0.3 (−11.4 to 10.8) 0.96
Necrotizing enterocolitis stage 2 or 3 3 (2.0) 7 (4.6) −2.7 (−6.7 to 1.4) 0.20
Isolated intestinal perforation 1 (0.7) 2 (1.3) −0.7 (−2.9 to 1.6) 0.56
Laser surgery for retinopathy of prematurity 8 (5.3) 8 (5.3) 0.0 (−5.1 to 5.0) 0.99
Intraventricular hemorrhage grade 3 or 4 3 (2.0) 8 (5.3) −3.3 (−7.5 to 0.9) 0.12
Cystic periventricular leukomalacia 5 (3.3) 3 (2.0) 1.3 (−2.3 to 4.9) 0.48
Nasal trauma
Any documented 60 (39.5) 82 (54.3) −14.8 (−25.9 to −3.7) 0.01
Leading to change of treatment 8 (5.3) 27 (17.9) −12.6 (−19.7 to −5.5) 0.001
Caused by the assigned treatment 29 (19.1) 80 (53.0) −33.9 (−44.0 to −23.8) <0.001
* Positive values favor the CPAP group, and negative values favor the nasal-cannulae group.
† This event was prespecified as a serious adverse event.
‡ Infants who died before hospital discharge were excluded.
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pressure ventilation had not been permitted 
until nasal CPAP had failed, the risk difference 
for the primary outcome might have been 
smaller.
When appraising the result of a noninferiority 
trial, both the risk difference and its 95% confi-
dence interval are considered. Although our best 
estimation of the risk difference was 8.4 per-
centage points, we acknowledge that the upper 
limit of the 95% confidence interval was close to 
the margin of noninferiority (20 percentage points) 
and that slightly different failure rates in either 
group could have altered our conclusions.
Further research on the use of high-flow na-
sal cannulae in preterm and term newborn in-
fants is required. Since such cannulae are used 
with increasing frequency in the nontertiary care 
setting, randomized trials of high-flow nasal 
cannulae as primary respiratory support from 
birth will be important. We conclude that treat-
ment with high-flow nasal cannulae was non-
inferior to the use of nasal CPAP as respiratory 
support after extubation in very preterm infants. 
Since our trial was underpowered to show non-
inferiority in infants with a gestational age of 
less than 26 weeks, the use of high-flow nasal 
cannulae as first-line respiratory support after 
extubation in this extremely preterm group re-
quires caution.
Supported by a program grant (606789) and a Centre for 
Clinical Research Excellence grant (546519) from the National 
Health and Medical Research Council.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients’ families and the staff members who 
cared for them at the three participating centers, and research 
nurses Connie Wong, Donna Hovey, Louise Goodchild, and Ros 
Lontis for their assistance in recruitment and data collection.
References
1. Hamilton BE, Martin JA, Ventura SJ. 
Births: preliminary data for 2011. Nation-
al vital statistics reports. Vol. 61. No. 5. 
Hyattsville, MD: National Center for Health 
Statistics, 2012. (DHHS publication no. 
(PHS) 2013-1120.)
2. Davis P, Henderson-Smart D. Post-
extubation prophylactic nasal continuous 
positive airway pressure in preterm in-
fants: systematic review and meta-analysis. 
J Paediatr Child Health 1999;35:367-71.
3. Hough JL, Shearman AD, Jardine LA, 
Davies MW. Humidified high flow nasal 
cannulae: current practice in Australasian 
nurseries, a survey. J Paediatr Child Health 
2012;48:106-13.
4. Manley BJ, Owen L, Doyle LW, Davis 
PG. High-flow nasal cannulae and nasal 
continuous positive airway pressure use 
in non-tertiary special care nurseries in 
Australia and New Zealand. J Paediatr 
Child Health 2012;48:16-21.
5. Nath P, Ponnusamy V, Willis K, Bis-
sett L, Clarke P. Current practices of high 
and low flow oxygen therapy and humidi-
fication in UK neonatal units. Pediatr Int 
2010;52:893-4.
6. Hochwald O, Osiovich H. The use of 
high flow nasal cannulae in neonatal in-
tensive care units: is clinical practice con-
sistent with the evidence? J Neonat Perinat 
Med 2010;3:187-91.
7. Holleman-Duray D, Kaupie D, Weiss 
MG. Heated humidified high-f low nasal 
cannula: use and a neonatal early ex-
tubation protocol. J Perinatol 2007;27: 
776-81.
8. Shoemaker MT, Pierce MR, Yoder BA, 
DiGeronimo RJ. High flow nasal cannula 
versus nasal CPAP for neonatal respiratory 
disease: a retrospective study. J Perinatol 
2007;27:85-91.
9. Wilkinson D, Andersen C, O’Donnell 
CP, De Paoli AG. High flow nasal cannula 
for respiratory support in preterm in-
fants. Cochrane Database Syst Rev 2011; 
5:CD006405.
10. Manley BJ, Dold SK, Davis PG, Roehr 
CC. High-flow nasal cannulae for respira-
tory support of preterm infants: a review 
of the evidence. Neonatology 2012;102: 
300-8.
11. Shaffer TH, Alapati D, Greenspan JS, 
Wolfson MR. Neonatal non-invasive re-
spiratory support: physiological implica-
tions. Pediatr Pulmonol 2012;47:837-47.
12. Finer NN. Nasal cannula use in the 
preterm infant: oxygen or pressure? Pedi-
atrics 2005;116:1216-7.
13. Finer NN, Mannino FL. High-f low 
 nasal cannula: a kinder, gentler CPAP? 
J Pediatr 2009;154:160-2.
14. Piaggio G, Elbourne DR, Altman DG, 
Pocock SJ, Evans SJ. Reporting of non-
inferiority and equivalence randomized 
trials: an extension of the CONSORT state-
ment. JAMA 2006;295:1152-60. [Erratum, 
JAMA 2006;296:1842.]
15. Campbell DM, Shah PS, Shah V, Kelly 
EN. Nasal continuous positive airway pres-
sure from high flow cannula versus Infant 
Flow for preterm infants. J Perinatol 2006; 
26:546-9.
16. Collins CL, Holberton JR, Barfield C, 
Davis PG. A randomized controlled trial 
to compare heated humidified high-flow 
nasal cannulae with nasal continuous 
positive airway pressure postextubation 
in premature infants. J Pediatr 2012;162(5): 
949.e1-954.e1.
17. Miller SM, Dowd SA. High-flow nasal 
cannula and extubation success in the 
premature infant: a comparison of two 
modalities. J Perinatol 2010;30:805-8.
18. Spence KL, Murphy D, Kilian C, Mc-
Gonigle R, Kilani RA. High-flow nasal 
cannula as a device to provide continuous 
positive airway pressure in infants. J Peri-
natol 2007;27:772-5.
19. Kubicka ZJ, Limauro J, Darnall RA. 
Heated, humidified high-flow nasal can-
nula therapy: yet another way to deliver 
continuous positive airway pressure? Pe-
diatrics 2008;121:82-8.
20. Wilkinson DJ, Andersen CC, Smith K, 
Holberton J. Pharyngeal pressure with 
high-flow nasal cannulae in premature 
infants. J Perinatol 2008;28:42-7.
Copyright © 2013 Massachusetts Medical Society.
2013 icmje recommendations
The International Committee of Medical Journal Editors (ICMJE) has revised 
and renamed its Uniform Requirements. The new ICMJE Recommendations  
for the Conduct, Reporting, Editing and Publication of Scholarly Work  
in Medical Journals are available at www.icmje.org.
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on March 26, 2017. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
